Skip to content

Study · Non-randomized trial · n = 25 · 1994

9 results

Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial.

Brown CS, Ling FW, Andersen RN, Farmer RG, Arheart KL

Obstetrics and gynecology1 Nov 1994Cited by 70 (Europe PMC)

PMID7936512 (opens in a new tab)PepBankPUB-07936512
Publisher pageAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with PMS, leuprolide improved all rating scales significantly more than placebo.

    In plain wordsLeuprolide improved all PMS rating scales more than placebo.

    Peptide
    Leuprolide
    Outcome
    DecreaseOverall rating scales
    Study

    n = 25

    Comparator
    Placebo
    Outcome group
    Premenstrual symptoms · Reproductive and sexual health
    Studied dose
    3.75 mg/month · intramuscular · three consecutive treatment cyclesAs given in this study (human).

    Source sentences

    Summary
    Depot leuprolide treatment was significantly more effective than placebo on all rating scales.
    2 context sentences
    Summary · context
    Twenty-five women who met strict diagnostic criteria for PMS completed a double-blind, placebo-controlled, 6-month crossover trial at a university medical center.
    Summary · context
    Depot leuprolide (3.75 mg/month) or saline was administered intramuscularly for three consecutive treatment cycles.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with PMS, irritability, neurologic symptoms, breast tenderness, and fatigue were the symptoms most responsive to leuprolide.

    In plain wordsIrritability, neurologic symptoms, breast tenderness, and fatigue were the PMS symptoms most responsive to leuprolide.

    Peptide
    Leuprolide
    Outcome
    DecreaseMost responsive symptom domains
    Study

    n: not reported in source

    Outcome group
    Premenstrual symptoms · Reproductive and sexual health
    Studied dose
    3.75 mg/month · intramuscular · three consecutive treatment cyclesAs given in this study (human).

    Source sentences

    Summary
    Irritability, neurologic symptoms, breast tenderness, and fatigue were most responsive to treatment.
    2 context sentences
    Summary · context
    Twenty-five women who met strict diagnostic criteria for PMS completed a double-blind, placebo-controlled, 6-month crossover trial at a university medical center.
    Summary · context
    Depot leuprolide (3.75 mg/month) or saline was administered intramuscularly for three consecutive treatment cycles.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with PMS, leuprolide suppressed estradiol in most premenstrual depression groups.

    In plain wordsLeuprolide suppressed estradiol in most premenstrual depression groups.

    Peptide
    Leuprolide
    Outcome
    DecreaseEstradiol
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg/month · intramuscular · three consecutive treatment cyclesAs given in this study (human).

    Source sentences

    Summary
    Leuprolide suppressed estradiol and progesterone in most premenstrual depression groups but had varying effects on gonadotropins.
    2 context sentences
    Summary · context
    Twenty-five women who met strict diagnostic criteria for PMS completed a double-blind, placebo-controlled, 6-month crossover trial at a university medical center.
    Summary · context
    Depot leuprolide (3.75 mg/month) or saline was administered intramuscularly for three consecutive treatment cycles.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with PMS, leuprolide suppressed progesterone in most premenstrual depression groups.

    In plain wordsLeuprolide suppressed progesterone in most premenstrual depression groups.

    Peptide
    Leuprolide
    Outcome
    DecreaseProgesterone
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg/month · intramuscular · three consecutive treatment cyclesAs given in this study (human).

    Source sentences

    Summary
    Leuprolide suppressed estradiol and progesterone in most premenstrual depression groups but had varying effects on gonadotropins.
    2 context sentences
    Summary · context
    Twenty-five women who met strict diagnostic criteria for PMS completed a double-blind, placebo-controlled, 6-month crossover trial at a university medical center.
    Summary · context
    Depot leuprolide (3.75 mg/month) or saline was administered intramuscularly for three consecutive treatment cycles.
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with PMS, leuprolide had varying effects on gonadotropins.

    In plain wordsLeuprolide had varying effects on gonadotropins in women with PMS.

    Peptide
    Leuprolide
    Outcome
    MixedGonadotropins
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg/month · intramuscular · three consecutive treatment cyclesAs given in this study (human).

    Source sentences

    Summary
    Leuprolide suppressed estradiol and progesterone in most premenstrual depression groups but had varying effects on gonadotropins.
    2 context sentences
    Summary · context
    Twenty-five women who met strict diagnostic criteria for PMS completed a double-blind, placebo-controlled, 6-month crossover trial at a university medical center.
    Summary · context
    Depot leuprolide (3.75 mg/month) or saline was administered intramuscularly for three consecutive treatment cycles.
  6. 06HumanObservational studyEfficacy outcome

    In leuprolide-treated women without premenstrual depression, symptoms decreased to follicular phase levels.

    In plain wordsWith leuprolide, PMS symptoms decreased to follicular phase levels in women without premenstrual depression.

    Peptide
    Leuprolide
    Outcome
    DecreaseSymptoms without premenstrual depression
    Study

    n: not reported in source

    Outcome group
    Premenstrual symptoms · Reproductive and sexual health
    Studied dose
    3.75 mg/month · intramuscular · three consecutive treatment cyclesAs given in this study (human).

    Source sentences

    Summary
    Symptoms were reduced to follicular phase levels only in women without premenstrual depression.
    2 context sentences
    Summary · context
    Twenty-five women who met strict diagnostic criteria for PMS completed a double-blind, placebo-controlled, 6-month crossover trial at a university medical center.
    Summary · context
    Depot leuprolide (3.75 mg/month) or saline was administered intramuscularly for three consecutive treatment cycles.
  7. 07HumanObservational studyEfficacy outcome

    In leuprolide-treated women with moderate premenstrual depression, symptoms improved but remained clinically evident.

    In plain wordsWith leuprolide, women with moderate premenstrual depression improved but remained symptomatic.

    Peptide
    Leuprolide
    Outcome
    DecreaseSymptoms with moderate premenstrual depression
    Study

    n: not reported in source

    Outcome group
    Premenstrual symptoms · Reproductive and sexual health
    Studied dose
    3.75 mg/month · intramuscular · three consecutive treatment cyclesAs given in this study (human).

    Source sentences

    Summary
    Those with moderate premenstrual depression improved but remained clinically symptomatic, whereas the group with severe premenstrual depression showed no improvement on any efficacy measure.
    2 context sentences
    Summary · context
    Twenty-five women who met strict diagnostic criteria for PMS completed a double-blind, placebo-controlled, 6-month crossover trial at a university medical center.
    Summary · context
    Depot leuprolide (3.75 mg/month) or saline was administered intramuscularly for three consecutive treatment cycles.
  8. 08HumanObservational studyEfficacy outcome

    In leuprolide-treated women with severe premenstrual depression, no efficacy measure improved.

    In plain wordsWith leuprolide, women with severe premenstrual depression showed no improvement on any efficacy measure.

    Peptide
    Leuprolide
    Outcome
    No significant changeSymptoms with severe premenstrual depression
    Study

    n: not reported in source

    Outcome group
    Premenstrual symptoms · Reproductive and sexual health
    Studied dose
    3.75 mg/month · intramuscular · three consecutive treatment cyclesAs given in this study (human).

    Source sentences

    Summary
    Those with moderate premenstrual depression improved but remained clinically symptomatic, whereas the group with severe premenstrual depression showed no improvement on any efficacy measure.
    2 context sentences
    Summary · context
    Twenty-five women who met strict diagnostic criteria for PMS completed a double-blind, placebo-controlled, 6-month crossover trial at a university medical center.
    Summary · context
    Depot leuprolide (3.75 mg/month) or saline was administered intramuscularly for three consecutive treatment cycles.
  9. 09HumanObservational studySafety outcome

    Among leuprolide-treated women, adverse events were lowest without premenstrual depression and highest with severe depression.

    In plain wordsWith leuprolide, adverse events were lowest without premenstrual depression and highest with severe depression.

    Peptide
    Leuprolide
    Outcome
    MixedAdverse events by depression severity
    Study

    n: not reported in source

    Comparator
    Other premenstrual depression severity groups
    Outcome group
    Adverse events · Whole body
    Studied dose
    3.75 mg/month · intramuscular · three consecutive treatment cyclesAs given in this study (human).

    Source sentences

    Summary
    Adverse events were lowest in those without premenstrual depression and highest in those with severe depression.
    2 context sentences
    Summary · context
    Twenty-five women who met strict diagnostic criteria for PMS completed a double-blind, placebo-controlled, 6-month crossover trial at a university medical center.
    Summary · context
    Depot leuprolide (3.75 mg/month) or saline was administered intramuscularly for three consecutive treatment cycles.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.